Navigation Links
MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Date:8/12/2008

SAN DIEGO, Aug. 12 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, today announced the completion of two separate licensing agreements with the Memorial Sloan-Kettering Cancer Center's Sloan-Kettering Institute for Cancer Research (SKI).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080812/LATU515LOGO)

The first license agreement grants MabVax exclusive development and commercialization rights to multiple vaccines against recurrent cancer for six different types of cancer. MSKCC plans to initiate Phase I clinical trials in each of these types of cancer this year or early next year. Upon successful demonstration of immunogenicity and tolerability in the Phase I trials in sarcoma and small cell lung cancer, MabVax will initiate Phase II trials in these two cancer types. In addition to MabVax's efforts, MSKCC is planning to conduct Phase II trials with the licensed vaccines in ovarian and breast cancer. Pending successful outcomes, MabVax can assume responsibility for continued development and eventual commercialization of these vaccines.

The second license agreement grants MabVax exclusive rights to the use of the licensed vaccines and lymphocytes from successfully vaccinated clinical trial participants. MabVax plans to rescue antibodies from these patient samples to create a pipeline of fully human monoclonal antibody products against each of the vaccine targets expressed on the surface of the cancer cells. By rescuing antibodies from a selection of patients who generate a useful immune response, MabVax can select the optimal antibodies and develop them as either stand alone products or as combination products with the vaccines. MabVax has established a laboratory and office in the San Diego area to launch this effort.

"The completion of these two agreements establishes the scientific foundation of the company and firmly set us on a research and development pathway that we hope will address a significant unmet medical need by preventing recurrence in certain types of cancers and prolonging patient survival," said David Hansen, the company's President and Chief Executive Officer. Philip Livingston, M.D., the company's Chief Science Officer and co-founder of MabVax added, "Targeting residual circulating cancer cells and micrometastasis with passively administered or vaccine induced antibodies against multiple targets is an approach well suited to eradicating the cancer cells that cause metastatic disease. Our clinical trials over the next several years will tell us a great deal about the utility of this approach to treating cancer."

About MabVax Therapeutics, Inc.

MabVax was formed to commercialize the work of Dr. Phil Livingston and colleagues at Memorial Sloan-Kettering Cancer Center (MSKCC) who over the last 25 years have developed monovalent cancer vaccines against ten distinct antigenic targets on various types of cancer cells. These vaccines target gangliosides and other carbohydrate antigens that are the most extensively expressed antigenic targets on the cell surface of certain cancers. Vaccines, or passively administered antibodies developed from these vaccines, produced evidence demonstrating the prevention of tumor recurrence and prolonged survival in preclinical models and supporting data in early Phase I human clinical trials. The company is initially focused on developing polyvalent vaccines and a pipeline of fully human monoclonal antibodies to address a variety of cancers including sarcoma, small cell lung cancer, and melanoma. MabVax closed a Series A venture financing with GBP Capital in late February 2008.


'/>"/>
SOURCE MabVax Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):